NCT05224336

Psilocybin-assisted Therapy for Phantom Limb Pain

Behavioral and Neural Mechanisms Supporting Psilocybin-assisted Therapy for Phantom Limb Pain

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: University of California, San Diego · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This double-blind placebo-controlled pilot study seeks to investigate whether psilocybin can be safely administered to people with chronic phantom limb pain (PLP) in a supportive setting with close follow-up, and its effects on pain symptoms and other moods, attitudes, and behaviors. The investigators' primary hypotheses are that psilocybin is safe to administer in people with PLP and that it will reduce scores on measures of pain. The investigators will also assess a number of secondary measures related to the behavioral and neural responses to pain after psilocybin treatment.

Conditions

• Phantom Limb Pain

Interventions

Type	Name	Description
DRUG	Psilocybin	25mg oral psilocybin
DRUG	Placebo Niacin	100mg oral niacin

Timeline

• Start date: 2022-10-03
• Primary completion: 2024-03-07
• Completion: 2024-03-07
• First posted: 2022-02-04
• Last updated: 2026-01-09

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study